SCLC-J1, a novel small cell lung cancer cell line

Kazuo Ohara; Shintaro Kinoshita; Jun Ando; Yoko Azusawa; Midori Ishii; Sakiko Harada; Yoichiro Mitsuishi; Tetsuhiko Asao; Ken Tajima; Taketsugu Yamamoto; Fumiyuki Takahashi; Norio Komatsu; Kazuhisa Takahashi; Miki Ando

doi:10.1016/j.bbrep.2021.101089

SCLC-J1, a novel small cell lung cancer cell line

Biochem Biophys Rep. 2021 Jul 28:27:101089. doi: 10.1016/j.bbrep.2021.101089. eCollection 2021 Sep.

Authors

Affiliations

¹ Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
² Department of Transfusion Medicine and Stem Cell Regulation, Japan.
³ Department of Respiratory Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
⁴ Department of Thoracic Surgery, Yokohama Rosai Hospital, 3211, Kozukue, Kohoku-ku, Yokohama, Kanagawa, Japan.
⁵ Division of Stem Cell Therapy, Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.

Abstract

Small cell lung cancer (SCLC) is a type of high-grade neuroendocrine carcinoma. It initially responds to chemotherapy but rapidly becomes chemoresistant and it is highly proliferative. The prognosis in SCLC is poor. We have established a novel SCLC cell line, SCLC-J1, from a malignant pleural effusion in a patient with advanced SCLC. SCLC-J1 cells express ganglioside GD2, CD276, and Delta-like protein 3. RB1 is lost. These features of the new SCLC cell line may be useful in understanding the cellular and molecular biology of SCLC and in designing better treatment.

Keywords: B7-H3; DLL3; Established SCLC cell line; GD2; Small cell lung cancer; Somatic mutations.